A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

The combined influence of oncogenic drivers, genomic instability, and/or DNA damage repair deficiencies increases replication stress in cancer. Cells with high replication stress rely on the upregulation of checkpoints like those governed by CHK1 for survival. Previous studies of the CHK1 inhibitor prexasertib demonstrated activity across multiple cancer types. Therefore, we sought to (1) identify markers of prexasertib sensitivity and (2) define the molecular mechanism(s) of intrinsic and acquired resistance using preclinical models representing multiple tumor types. Our findings indicate that while cyclin E dysregulation is a driving mechanism of prexasertib response, biomarkers associated with this aberration lack sufficient predictive power to render them clinically actionable for patient selection. Transcriptome analysis of a pan-cancer cell line panel and in vivo models revealed an association between expression of E2F target genes and prexasertib sensitivity and identified innate immunity genes associated with prexasertib resistance. Functional RNAi studies supported a causal role of replication fork components as modulators of prexasertib response. Mechanisms that protect cells from oncogene-induced replication stress may safeguard tumors from such stress induced by a CHK1 inhibitor, resulting in acquired drug resistance. Furthermore, resistance to prexasertib may be shaped by innate immunity.

[1]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[2]  Grant W. Brown,et al.  Exploiting DNA Replication Stress for Cancer Treatment. , 2019, Cancer research.

[3]  R. Syljuåsen,et al.  p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775 , 2019, Cell cycle.

[4]  K. Flatten,et al.  Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo , 2019, Scientific Reports.

[5]  J. Moreaux,et al.  Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner , 2019, Nature Communications.

[6]  Jing Wang,et al.  Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. , 2019, Cancer discovery.

[7]  K. Cole,et al.  Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models , 2018, Clinical Cancer Research.

[8]  G. Freeman,et al.  PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer , 2018, Cell reports.

[9]  Arun Kumar,et al.  Chromatin as a Platform for Modulating the Replication Stress Response , 2018, Genes.

[10]  G. Tseng,et al.  Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles , 2018, Oncogene.

[11]  G. Mills,et al.  State-of-the-art strategies for targeting the DNA damage response in cancer , 2018, Nature Reviews Clinical Oncology.

[12]  B. Fahrenkrog,et al.  Histone H4K20 methylation mediated chromatin compaction threshold ensures genome integrity by limiting DNA replication licensing , 2018, Nature Communications.

[13]  Juanita Lopez,et al.  Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies , 2018, Therapeutic advances in medical oncology.

[14]  N. Gray,et al.  Structure of the Human cGAS–DNA Complex Reveals Enhanced Control of Immune Surveillance , 2018, Cell.

[15]  S. Boulton,et al.  Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place. , 2018, Cancer discovery.

[16]  V. Costanzo,et al.  SAMHD1 acts at stalled replication forks to prevent interferon induction , 2018, Nature.

[17]  Suzanne F. Jones,et al.  Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma , 2018, Clinical Cancer Research.

[18]  S. Steinberg,et al.  Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study , 2018, The Lancet. Oncology.

[19]  C. Caldwell,et al.  Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. , 2017, Cancer cell.

[20]  Giovanna Damia,et al.  DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. , 2017, Cancer treatment reviews.

[21]  M. Ferrer,et al.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. , 2017, Cancer discovery.

[22]  You-Sun Kim,et al.  Nuclear TRADD prevents DNA damage-mediated death by facilitating non-homologous end-joining repair , 2017, Scientific Reports.

[23]  Y. Drew,et al.  Targeting the ATR-CHK1 Axis in Cancer Therapy , 2017, Cancers.

[24]  R. Beckmann,et al.  Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair , 2017, Clinical Cancer Research.

[25]  R. Beckmann,et al.  The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma , 2017, Clinical Cancer Research.

[26]  E. Wakeland,et al.  RAD51 interconnects between DNA replication, DNA repair and immunity , 2017, Nucleic acids research.

[27]  D. Baker,et al.  Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation , 2016, Science.

[28]  Suzanne F. Jones,et al.  Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Kuster,et al.  A bead-based western for high-throughput cellular signal transduction analyses , 2016, Nature Communications.

[30]  H. Haller,et al.  CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling , 2016, Cell Death and Disease.

[31]  B. Schumacher,et al.  DNA Damage Response and Immune Defense: Links and Mechanisms , 2016, Front. Genet..

[32]  R. D. de Bruin,et al.  Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage , 2016, Cell reports.

[33]  J. Dempsey,et al.  LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms , 2015, Molecular Cancer Therapeutics.

[34]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[35]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[36]  S. Pradhan,et al.  MCM Paradox: Abundance of Eukaryotic Replicative Helicases and Genomic Integrity , 2014, Molecular biology international.

[37]  N. Mailand,et al.  ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA , 2013, Cell.

[38]  W. McDonald,et al.  Identification of Proteins at Active, Stalled, and Collapsed Replication Forks Using Isolation of Proteins on Nascent DNA (iPOND) Coupled with Mass Spectrometry* , 2013, The Journal of Biological Chemistry.

[39]  T. Helleday,et al.  Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress , 2013, Oncogene.

[40]  M. Christmann,et al.  Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation , 2013, Nucleic acids research.

[41]  A. Rojas,et al.  A proteomic characterization of factors enriched at nascent DNA molecules. , 2013, Cell reports.

[42]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[43]  J. Diffley,et al.  Controlling DNA replication origins in response to DNA damage – inhibit globally, activate locally , 2013, Journal of Cell Science.

[44]  A. Eastman,et al.  The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition , 2012, PloS one.

[45]  M. Rosner,et al.  An integrated view of cyclin E function and regulation , 2012, Cell cycle.

[46]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[47]  James M. Roberts,et al.  Cyclin A Promotes S-Phase Entry via Interaction with the Replication Licensing Factor Mcm7 , 2010, Molecular and Cellular Biology.

[48]  Gurpreet W. Tang,et al.  The Catalogue of Somatic Mutations in Cancer , 2009 .

[49]  E. Schwob,et al.  Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication , 2008, Proceedings of the National Academy of Sciences.

[50]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Hui Zhao,et al.  Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52]  H. F. Horn,et al.  Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication , 2000, Cell.

[53]  A. Asaithamby,et al.  Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling. , 2019, Advances in protein chemistry and structural biology.

[54]  Lye Mun Tho,et al.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[56]  J. Tobin.  Estimation of Relationships for Limited Dependent Variables , 1958 .